"Moderna's Stock Soars as Analysts Predict a Productive Pipeline Boosting Market Performance"

Moderna's stock surged over 15% following an upgrade by Oppenheimer to "outperform," with predictions that the company could launch up to five new products by 2026. Despite a tough 2023 due to declining demand for Covid vaccines, Oppenheimer anticipates a rebound in Covid vaccine sales and is optimistic about Moderna's pipeline, including potential approvals for an RSV vaccine in April, a flu vaccine in the next couple of years, and a personalized cancer vaccine in partnership with Merck. These developments have sparked investor confidence and driven up Moderna's stock price.